Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2015 - 2026)

Syndax Pharmaceuticals' Accumulated Expenses history runs 12 years deep, the most recent figure standing at $74.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 911.12% year-over-year to $74.8 million in Q1 2026; TTM through Mar 2026 was $74.8 million, a 911.12% increase from a year earlier, with the FY2025 full-year figure at $103.1 million, up 71.5% from the prior year.
• Accumulated Expenses retreated to $74.8 million in Q1 2026 per SNDX's latest filing, from $103.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $103.1 million in Q4 2025 and bottomed at $1.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $24.3 million (2022), against an average of $31.3 million.
• Across the five-year window, Accumulated Expenses surged 994.2% in 2024 and slumped 77.84% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $24.3 million in 2022, then jumped by 64.18% to $39.9 million in 2023, then jumped by 50.78% to $60.1 million in 2024, then soared by 71.5% to $103.1 million in 2025, then declined by 27.38% to $74.8 million in 2026.
• Per Business Quant, the three latest SNDX Accumulated Expenses figures stand at $74.8 million (Q1 2026), $103.1 million (Q4 2025), and $15.6 million (Q3 2025).